Do Lignin Nanoparticles Pave the Way for a Sustainable Nanocircular Economy? Biostimulant Effect of Nanoscaled Lignin in Tomato Plants.

Agriculture has a significant environmental impact and is simultaneously called to major challenges, such as responding to the need to develop more sustainable cropping systems with higher productivity. In this context, the present study aimed to obtain lignin nanoparticles (LNs) from pomace, a waste product of the olive oil chain, to be used as a nanobiostimulant in tomato plants. The biostimulant effect of this biopolymer is known, but its reduction to nanometer size can emphasize this property.

Cellulose Nanocrystals and Lignin Nanoparticles Extraction from L.: Acid Hydrolysis of Bleached and Ionic Liquid-Treated Biomass.

Using biomass to develop and obtain environmentally friendly and industrially applicable biomaterials is increasingly attracting global interest. Herein, cellulose nanocrystals (CNCs) and lignin nanoparticles (LNPs) were extracted from L., a freshwater free-floating aquatic species commonly called duckweed.

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.

Background: Immunotherapy combined with chemotherapy significantly improves progression-free survival (PFS) compared to first-line chemotherapy alone in advanced endometrial cancer (EC), with a much larger effect size in microsatellite instability-high (MSI-H) cases. New biomarkers might help to select patients who may have benefit among those with a microsatellite-stable (MSS) tumor.

Patients And Methods: In a pre-planned translational analysis of the MITO END-3 trial, we assessed the significance of genomic abnormalities in patients randomized to standard carboplatin/paclitaxel without or with avelumab.

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

Background: Adding immunotherapy to first-line chemotherapy might improve outcomes for patients with advanced or recurrent endometrial cancer. We aimed to compare carboplatin and paclitaxel versus avelumab plus carboplatin and paclitaxel as first-line treatment with avelumab given concurrent to chemotherapy and as maintenance after the end of chemotherapy.

Methods: MITO END-3 is an open-label, randomised, controlled, phase 2 trial conducted at 31 cancer institutes, hospitals, and universities in Italy.

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.

Objective: The aim of the present analysis was to explore the efficacy of Bevacizumab (Bev) on survival outcome in advanced low grade serous ovarian cancer (LGSOC) both in first line and in recurrent setting.

Methods: In retrospective observational multicenter study, we described the outcome of LGSOC patients enrolled in the MITO 22 study and treated with chemotherapy (CT) with or without Bev. Patients receiving Bev in first-line or in recurrence were considered and compared with patients receiving CT alone (stage III and IV in first line; platinum based-CT in second line).